Patrizio Armando, Ferrari Silvia Martina, Elia Giusy, Ragusa Francesca, Paparo Sabrina Rosaria, Mazzi Valeria, Antonelli Alessandro, Fallahi Poupak
Department of Emergency Medicine, Azienda Ospedaliero-Universitaria Pisana, 56124 Pisa, Italy.
Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy.
Vaccines (Basel). 2022 Sep 1;10(9):1445. doi: 10.3390/vaccines10091445.
(1) Background: Autoimmune diseases, including autoimmune endocrine diseases (AIED), are thought to develop following environmental exposure in patients with genetic predisposition. The vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could represent a new environmental trigger for AIED, including Graves' disease (GD). (2) Methods: We performed a literature search of MEDLINE/PubMed databases regarding thyroid dysfunction after SARS-CoV-2 vaccination since 1 January 2020 to 31 July 2022, considering only cases of thyrotoxicosis that meet the 2016 American Thyroid Association guidelines criteria for the diagnosis of GD and arising after administration of the anti-SARS-CoV-2 vaccine, regardless of the number of doses. (3) Results: A total of 27 articles were identified, consisting of case reports or case series, of which 24 describe the appearance of 48 new diagnoses of GD and 12 GD recurrences arising after the administration of the anti-SARS-CoV-2 vaccine, and 3 papers that instead report only 3 cases of GD relapse following vaccination. (4) Conclusions: physicians should be aware of the possibility of developing GD and other autoimmune sequelae following SARS-CoV-2 vaccination. Regardless of the underlying pathogenetic mechanisms (autoimmune/inflammatory syndrome induced by adjuvants (ASIA syndrome), cytokines induction, molecular mimicry, and cross-reactivity), an individual predisposition seems to be decisive for their development.
(1)背景:自身免疫性疾病,包括自身免疫性内分泌疾病(AIED),被认为是在具有遗传易感性的患者接触环境因素后发生的。针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的疫苗可能成为AIED(包括格雷夫斯病(GD))的新环境触发因素。(2)方法:我们对MEDLINE/PubMed数据库进行了文献检索,以查找2020年1月1日至2022年7月31日期间接种SARS-CoV-2疫苗后出现的甲状腺功能障碍情况,仅考虑符合2016年美国甲状腺协会GD诊断指南标准且在接种抗SARS-CoV-2疫苗后出现的甲状腺毒症病例,无论接种剂量多少。(3)结果:共识别出27篇文章,包括病例报告或病例系列,其中24篇描述了接种抗SARS-CoV-2疫苗后出现的48例新诊断GD和12例GD复发,另有3篇文章仅报告了接种疫苗后3例GD复发。(4)结论:医生应意识到接种SARS-CoV-2疫苗后发生GD和其他自身免疫性后遗症的可能性。无论潜在的致病机制(佐剂诱导的自身免疫/炎症综合征(ASIA综合征)、细胞因子诱导、分子模拟和交叉反应)如何,个体易感性似乎对其发生起决定性作用。